Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine

Clinical and Vaccine Immunology

Volumn 16, Issue 4, 2009, Pages 499-505

  Wang, Yichuan ^a,b   Blozis, Shelley A ^c   Lederman, Michael ^d   Krieg, Arthur ^e   Landay, Alan ^b   Miller, Christopher J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; EMTRICITABINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; TENOFOVIR; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

2,2'-DIPYRIDYL; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISINFECTANTS; DISULFIDES; HIV ANTIBODIES; INTERFERON-GAMMA; MACACA MULATTA; OLIGODEOXYRIBONUCLEOTIDES; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIRAL LOAD; VIRUS INACTIVATION;

EID: 64549097621     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00471-08     Document Type: Article

References (44)

1. Abel, K., L. Compton, T. Rourke, D. Montefiori, D. Lu, K. Rothaeusler, L. Fritts, K. Bost, and C. J. Miller. 2003. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J. Virol. 77:3099-3118.
2. Abel, K., L. La Franco-Scheuch, T. Rourke, Z.-M. Ma, V. de Silva, B. Fallert, L. Beckett, T. A. Reinhart, and C. J. Miller. 2004. Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques. J. Virol. 78:841-854.
3. Abel, K., Y. Wang, L. Fritts, E. Sanchez, E. Chung, P. Fitzgerald-Bocarsly, A. M. Krieg, and C. J. Miller. 2005. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin. Diagn. Lab. Immunol. 12:606-621.
4. Arthur, L. O., J. W. Bess, Jr., E. N. Chertova, J. L. Rossio, M. T. Esser, R. E. Benveniste, L. E. Henderson, and J. D. Lifson. 1998. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum Retrovir. 14(Suppl. 3):S311-S319.
5. Autran, B., B. Sadat-Sowti, F. Hadida, A. Parrot, J. M. Guillon, F. Plata, C. Mayaud, and P. Debre. 1991. HIV-specific cytotoxic T lymphocytes against alveolar macrophages: specificities and downregulation. Res. Virol. 142:113-118.
6. Betts, M. R., J. F. Krowka, T. B. Kepler, M. Davidian, C. Christopherson, S. Kwok, L. Louie, J. Eron, H. Sheppard, and J. A. Frelinger. 1999. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res. Hum. Retrovir. 15:1219-1228.
7. + T cells in peripheral blood after initiation of highly active antiretroviral therapy. J. Virol. 75:6508-6516.
8. Cecchinato, V., E. Tryniszewska, Z. M. Ma, M. Vaccari, A. Boasso, W. P. Tsai, C. Petrovas, D. Fuchs, J. M. Heraud, D. Venzon, G. M. Shearer, R. A. Koup, I. Lowy, C. J. Miller, and G. Franchini. 2008. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J. Immunol. 180:5439-5447.
9. Chertova, E., B. J. Crise, D. R. Morcock, J. W. Bess, Jr., L. E. Henderson, and J. D. Lifson. 2003. Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins. Curr. Mol. Med. 3:265-272.
10. Chun, T. W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y. H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch-Crovo, and R. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
11. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
12. Dailey, P. J., M. Zamround, R. Kelso, J. Kolberg, and M. Urdea. 1995. Quantification of simian immunodeficiency virus (SIV) RNA in plasma of acute and chronically infected macaques using a branched DNA (bDNA) signal amplification assay, p.180.13th Annu. Symp. Nonhum. Primate Models AIDS, Monterey, CA.
13. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
14. Fuller, D. H., P. A. Rajakumar, M. S. Wu, C. W. McMahon, T. Shipley, J. T. Fuller, A. Bazmi, A. M. Trichel, T. M. Allen, B. Mothe, J. R. Haynes, D. I. Watkins, and M. Murphey-Corb. 2006. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 348:200-215.
15. Gelman, A. E., J. Zhang, Y. Choi, and L. A. Turka. 2004. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J. Immunol. 172: 6065-6073.
16. Haase, A. T. 1999. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu. Rev. Immunol. 17:625-656.
17. He, B., X. Qiao, and A. Cerutti. 2004. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J. Immunol. 173:4479-4491.
18. Hryniewicz, A., D. A. Price, M. Moniuszko, A. Boasso, Y. Edghill-Spano, S. M. West, D. Venzon, M. Vaccari, W. P. Tsai, E. Tryniszewska, J. Nacsa, F. Villinger, A. A. Ansari, C. J. Trindade, M. Morre, D. Brooks, P. Arlen, H. J. Brown, C. M. Kitchen, J. A. Zack, D. C. Douek, G. M. Shearer, M. G. Lewis, R. A. Koup, and G. Franchini. 2007. Interleukin-15 but not interleu-kin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J. Immunol. 178:3492-3504.
19. Jung, J., A. K. Yi, X. Zhang, J. Choe, L. Li, and Y. S. Choi. 2002. Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J. Immunol. 169:2368-2373.
20. Kalams, S. A., P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, G. S. Ogg, and B. D. Walker. 1999. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:6721-6728.
21. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs inbacterial DNA trigger direct B-cell activation. Nature 374:546-549.
22. Kuwajima, S., T. Sato, K. Ishida, H. Tada, H. Tezuka, and T. Ohteki. 2006. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat. Immunol. 7:740-746.
23. Kwissa, M., R. R. Amara, H. L. Robinson, B. Moss, S. Alkan, A. Jabbar, F. Villinger, and B. Pulendran. 2007. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J. Exp. Med. 204:2733-2746.
24. Liu, N., N. Ohnishi, L. Ni, S. Akira, and K. B. Bacon. 2003. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol. 4:687-693.
25. Lu, W., L. C. Arraes, W. T. Ferreira, and J. M. Andrieu. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
26. Lu, W., X. Wu, Y. Lu, W. Guo, and J. M. Andrieu. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9:27-32.
27. +-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV. J. Virol. 72:10029-10035.
28. Mueller, Y. M., D. H. Do, S. R. Altork, C. M. Artlett, E. J. Gracely, C. D. Katsetos, A. Legido, F. Villinger, J. D. Altman, C. R. Brown, M. G. Lewis, and P. D. Katsikis. 2008. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J. Immunol. 180:350-360.
29. Pillay, D., S. Taylor, and D. D. Richman. 2000. Incidence and impact of resistance against approved antiretroviral drugs. Rev. Med. Virol. 10:231-253.
30. Rossio, J. L., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, L. O. Arthur, L. E. Henderson, and J. D. Lifson. 1998. Inactivationofhuman immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
31. Teleshova, N., J. Kenney, J. Jones, J. Marshall, G. Van Nest, J. Dufour, R. Bohm, J. D. Lifson, A. Gettie, and M. Pope. 2004. CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells. J. Immunol. 173:1647-1657.
32. Uberla, K., B. Rosenwirth, P. Ten Haaft, J. Heeney, G. Sutter, and V. Erfle. 2007. Therapeutic immunization with modified vaccinia virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy. J. Med. Primatol. 36:2-9.
33. UNAIDS. 2006. 2006 report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland.
34. Valdez, H., E. Connick, K. Y. Smith, M. M. Lederman, R. J. Bosch, R. S. Kim, M. St. Clair, D. R. Kuritzkes, H. Kessler, L. Fox, M. Blanchard-Vargas, and A. Landay. 2002. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 16:1859-1866.
35. +-cell-me-diated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J. Virol. 78:5324-5337.
36. Veazey, R. S., M. DeMaria, L. V. Chalifoux, D. E. Shvetz, D. R. Pauley, H. L. Knight, M. Rosenzweig, R. P. Johnson, R. C. Desrosiers, and A. A. Lackner. 1998. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280:427-431.
37. Veazey, R. S., P. A. Marx, and A. A. Lackner. 2003. Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J. Infect. Dis. 187:769-776.
38. Vigouroux, C., S. Gharakhanian, Y. Salhi, T. H. Nguyen, N. Adda, W. Rozenbaum, and J. Capeau. 1999. Adverse metabolic disorders duringhighly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 25:383-392.
39. von Gegerfelt, A. S., M. Rosati, C. Alicea, A. Valentin, P. Roth, J. Bear, G. Franchini, P. S. Albert, N. Bischofberger, J. D. Boyer, D. B. Weiner, P. Markham, Z. R. Israel, J. H. Eldridge, G. N. Pavlakis, and B. K. Felber. 2007. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J. Virol. 81:1972-1979.
40. Walker, C. M., and J. A. Levy. 1989. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology 66:628-630.
41. Wang, Y., K. Abel, K. Lantz, A. M. Krieg, M. B. McChesney, and C. J. Miller. 2005. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol. 79:14355-14370.
42. Wolfinger, R. D. 1999. Fitting nonlinear mixed models with the new NLMIXED procedure, paper 287. In Proceedings of the 24th Annual SAS Users Group International Conference, Miami Beach, FL. SAS Institute, Inc., Cary, NC.
43. Yi, A. K., M. Chang, D. W. Peckham, A. M. Krieg, and R. F. Ashman. 1998. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160:5898-5906.
44. Zhang, Z. Q., S. W. Wietgrefe, Q. Li, M. D. Shore, L. Duan, C. Reilly, J. D. Lifson, and A. T. Haase. 2004. Roles of substrate availability and infectionof resting and activated CD4 + T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 101:5640-5645.